760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

• William Redmond,
• Brendan Curti,
• John Cha,
• Walter Urba,
• Yoshinobu Koguchi,
• Brian Piening,
• Noriko Iwamoto,
• Takashi Shimada,
• Shu-Ching Chang

Affiliations

William Redmond

1Earle A. Chiles Research Institute, Portland, OR, USA

Brendan Curti

1 Providence Cancer Institute, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA

John Cha

1Providence Cancer Institute, Portland, OR, USA

Walter Urba

1Providence Cancer Institute, Portland, OR, USA

Yoshinobu Koguchi

1Providence Cancer Institute, Portland, OR, USA

Brian Piening

1Providence Cancer Institute, Portland, OR, USA

Noriko Iwamoto

2Shimadzu Scientific Instruments, Bothell, WA, USA

Takashi Shimada

2Shimadzu Scientific Instruments, Bothell, WA, USA

Shu-Ching Chang

3Providence St. Joseph Health, Portland, OR, USA